Skip to content
Alcaftadine
Lastacaft (alcaftadine) is a small molecule pharmaceutical. Alcaftadine was first approved as Lastacaft on 2010-07-28. It is used to treat allergic conjunctivitis in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
eye diseasesD005128
immune system diseasesD007154
Trade Name
FDA
EMA
Lastacaft
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Alcaftadine
Tradename
Company
Number
Date
Products
LASTACAFTAbbVieN-022134 OTC2010-07-28
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
lastacaftNew Drug Application2022-08-10
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
allergic conjunctivitisEFO_0007141D003233H10.44
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Alcaftadine, Lastacaft, Abbvie
86642152027-12-23U-3267
106176952027-03-19DPU-3267
ATC Codes
S: Sensory organ drugs
S01: Ophthalmologicals
S01G: Decongestants and antiallergics
S01GX: Other antiallergics in atc
S01GX11: Alcaftadine
HCPCS
No data
Clinical
Clinical Trials
605 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C50102832544
Pancreatic neoplasmsD010190EFO_0003860C25111733232
Liver cirrhosisD008103EFO_0001422K74.018481230
NeoplasmsD009369C801961224
AscitesD001201HP_0001541R182245517
Septic shockD012772A48.32562316
SepsisD018805A41.91372314
Acute kidney injuryD058186HP_0001919N1731610
Hepatorenal syndromeD006530K76.71631310
Squamous cell carcinoma of head and neckD000077195451110
Show 51 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD0022895164125
Stomach neoplasmsD013274EFO_0003897C165112318
Triple negative breast neoplasmsD064726471111
Uterine cervical neoplasmsD002583171110
Liver neoplasmsD008113EFO_1001513C22.021148
Neoadjuvant therapyD020360425
Alzheimer diseaseD000544EFO_0000249F032315
Covid-19D000086382U07.13115
Nasopharyngeal neoplasmsD0093031214
Prostatic neoplasmsD011471C612114
Show 29 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Esophageal squamous cell carcinomaD00007727721314
Ovarian neoplasmsD010051EFO_0003893C565712
FibrosisD005355358
Lung neoplasmsD008175C34.901617
AdenocarcinomaD0002302326
Chronic renal insufficiencyD051436N18336
Head and neck neoplasmsD006258325
MelanomaD008545134
Esophageal neoplasmsD004938C15244
ImmunotherapyD00716744
Show 68 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 1 diabetes mellitusD003922EFO_0001359E10123
Gallbladder neoplasmsD005706EFO_0004606C2322
Gastrointestinal stromal tumorsD046152EFO_0000505C49.A112
Subarachnoid hemorrhageD013345EFO_0000713I60112
Peritoneal neoplasmsD01053411
Prostatic hyperplasiaD011470EFO_0000284N4011
Salivary gland neoplasmsD012468EFO_0003826D1111
Tongue neoplasmsD014062EFO_0003871C02.911
Verrucous carcinomaD01828911
Central nervous system neoplasmsD01654311
Show 6 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Critical illnessD01663833
StrokeD020521EFO_0000712I63.922
Aortic valve diseaseD00008286222
Type 2 diabetes mellitusD003924EFO_0001360E1122
Inflammatory bowel diseasesD015212EFO_000376722
Colonic neoplasmsD003110C1822
Liver failureD017093HP_0001399K72.922
HemolysisD00646122
Coronary diseaseD00332711
Cardiogenic shockD012770R57.011
Show 63 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameALCAFTADINE
INNalcaftadine
Description
Alcaftadine is an imidazobenzazepine that is 6,11-dihydro-5H-imidazo[2,1-b][3]benzazepine substituted at position 3 by a formyl group and at position 11 by a 1-methylpiperidin-4-ylidene group. An antihistamine used for treatment of allergic conjunctivitis. It has a role as a H1-receptor antagonist and an anti-allergic agent. It is an aldehyde, a member of piperidines, an imidazobenzazepine and a tertiary amino compound.
Classification
Small molecule
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CN1CCC(=C2c3ccccc3CCn3c(C=O)cnc32)CC1
Identifiers
PDB
CAS-ID147084-10-4
RxCUI1000082
ChEMBL IDCHEMBL1201747
ChEBI ID71023
PubChem CID19371515
DrugBankDB06766
UNII ID7Z8O94ECSX (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 62 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,725 adverse events reported
View more details